DAVID MEDINA: Open Payments
NPI 1588805824 · ORLANDO, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$69,791 in 308 payments from 24 companies in 2025. Trend: 2023 $32,872 · 2024 $10,263 · 2025 $69,791
Speaker / faculty: $47,204Consulting: $8,550Food & beverage: $8,144Travel & lodging: $5,748Education: $145
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 103 | $48,972 |
| Otsuka America Pharmaceutical, Inc. | 22 | $15,248 |
| Axsome Therapeutics, Inc. | 25 | $1,054 |
| E.R. Squibb & Sons, L.L.C. | 21 | $744 |
| Teva Pharmaceuticals USA, Inc. | 22 | $648 |
| ABBVIE INC. | 17 | $498 |
| Alkermes, Inc. | 25 | $490 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 12 | $450 |
| Vanda Pharmaceuticals Inc. | 13 | $336 |
| Janssen Pharmaceuticals, Inc | 8 | $299 |
Products named: INGREZZA, REXULTI, Auvelity, COBENFY, AUSTEDO XR, CAPLYTA, VRAYLAR, ARISTADA.
Industry payments across FL — which companies pay providers there.
